CVS Caremark to Slash Osteoporosis Drug Costs by Over 50% with New Biosimilars
Beginning April 1, 2026, CVS Caremark will add osteoporosis biosimilars Ospomyv, Stoboclo and generic teriparatide products Bonsity and Tymlos to its major commercial formularies, replacing Amgen’s Prolia and Eli Lilly’s Forteo. CVS expects over 50% lower per‐prescription costs and cites a prior $1.5 billion gross savings from Humira biosimilar adoption.
1. New Formulary Additions and Timeline
Effective April 1, 2026, CVS Caremark will incorporate two osteoporosis biosimilars—Ospomyv from Cordavis Limited and Stoboclo from Celltrion Inc—and two generic teriparatide options, Bonsity and Tymlos, into its major national commercial template formularies. These additions will displace the branded therapies Prolia (denosumab) and Forteo (teriparatide) currently covered, marking a significant expansion of CVS’s biosimilar strategy.
2. Cost Savings and Financial Impact
CVS projects that the switch to these lower‐cost biosimilars and generics will reduce per‐prescription costs by more than 50% compared with the original brands. The company highlights prior successes, noting that removing Humira from its formulary in favor of biosimilars generated $1.5 billion in gross savings and achieved a 96% transition rate among client members.
3. Implementation and Patient Outreach
Formulary changes for specialty medications like Prolia will be managed by CVS Specialty, which will proactively reach out to both prescribers and patients to explain the updates and guide them through medication transitions. CVS emphasizes that biosimilars offer safe, effective alternatives with no clinically meaningful differences from reference products.